SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is facing significant volatility following a quarterly report that missed expectations due to margin pressures from its transition to branded weight-loss drugs. While the community is split between frustration over the earnings miss and optimism regarding raised full-year guidance and future peptide-related catalysts, traders are focused on how the platform's long-term pivot will impact its valuation.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is generating significant buzz as investors anticipate the upcoming Senate Banking Committee markup of the CLARITY Act, viewed by many as a potential catalyst for institutional adoption. Community sentiment is deeply divided, with bulls highlighting the project's utility and regulatory progress while critics continue to argue that the token's performance remains stagnant and speculative.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is currently experiencing extreme volatility as retail traders debate whether the stock is a speculative opportunity for exposure to high-growth AI and private companies or a dangerously overvalued asset trading far above its net asset value. Community discussions are dominated by sharp disagreements over the fund's NAV, concerns regarding insider share lockups, and intense speculation about potential IPO catalysts for its major holdings like Anthropic and SpaceX.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as it gains strong investor sentiment following the deployment of its Dirac-3 machine in the Quantum Corridor, fueling expectations for improved commercial revenue. Investors are closely monitoring its photonic technology, particularly its Thin-Film Lithium Niobate chips, while speculating on the stock's potential for a significant short squeeze given its high short interest and aggressive call buying.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is currently experiencing intense market volatility as investors weigh the company's aggressive infrastructure expansion and hyperscaler demand against significant earnings misses and supply chain bottlenecks. The stock remains a major talking point within the AI optics sector, with the community actively debating whether it is a critical piece of the data center buildout or a speculative bubble facing an inevitable correction.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is at a critical pivot point as the community debates its progress toward piloted transition flights and certification while monitoring its significant cash burn. Investors are closely scrutinizing upcoming earnings for updates on manufacturing scalability and commercial milestones, creating a high-volatility environment driven by both institutional positioning and speculation on the firm's path to revenue.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is seeing significant momentum and heightened community discussion driven by its pivot toward Edge AI and its specialized Associative Processing Unit (APU) technology, which supporters argue offers efficiency advantages in defense and autonomous drone applications. However, the stock remains a source of intense debate, as skeptical traders warn of potential rug-pulls and management transparency issues, pointing to past volatility and concerns over the company's reliance on legacy SRAM products versus its unproven AI hardware.

Twin Vee PowerCats Co. engages in the design, manufacture, and sale of recreational and commercial power catamaran boats. The firm is focused on designing and developing its products under the ELECTRA Power Sports brand. It operates through the Twin Vee PowerCats and Wizz Banger, Inc. Segments. The Twin Vee PowerCats segment designs, manufactures, and sells recreational and commercial powerboats. The Wizz Banger, Inc. segment refers to a development-stage subsidiary with plans to develop an innovative online marketplace leveraging artificial intelligence (AI) to transform how customers search for and purchase recreational marine assets. The company was founded by Roger Dunshee in 1996 and is headquartered in Fort Pierce, FL.

Twin Vee PowerCats Co

Twin Vee PowerCats is trending as retail traders target its extremely low float and post-reverse-split setup for a potential short squeeze. The community is heavily focused on the high cost-to-borrow and lack of available short shares, with many drawing comparisons to previous low-float runners.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is facing heavy retail scrutiny following a wider-than-expected net loss, with investors fiercely debating the company's strategic pivot toward AI infrastructure and energy management versus its historical volatility. The community is sharply divided between those calling for a leadership change due to perceived poor execution and those positioning for a potential squeeze, pinning their hopes on upcoming hyperscaler partnership announcements.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently experiencing extreme volatility driven by retail enthusiasm following a contract announcement for its subsidiary Lucid Diagnostics, but community sentiment is sharply divided due to concerns over massive dilution and the aggressive selling behavior of institutional PIPE investors. Discussions are dominated by active debates regarding potential share offerings and the tactical move by hedge funds to capture profits during high-volume swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues

Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.


Altimmune (ALT) Projected to Post Earnings on Tuesday

Altimmune (NASDAQ:ALT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-altimmune-inc-stock...

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead 

VKTX rose about 1.4% over the past month, beating Altimmune, Amgen, and Structure Therapeutics; however, Novo Nordisk led the pack with a 17.3% gain.

Equity

Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and s...

<ul class="summary-bullets"><li>Lululemon shares dropped after the company announced a new CEO who will take over in September.&nbsp;</li><li>Lucid investors were concerned about financial stability, despite new funding and a change in CEO.</li><li>&nbsp;Altimmune shares fell after a $225 million stock offering to fund its Phase 3 MASH trial.&nbsp;</li></ul>Lululemon Athletica Inc. (LULU), Lucid Group Inc. (LCID), and Altimmune Inc. (ALT) tumbled to fresh lows on Thursday, reflecting growing skepticism toward once-favored growth narratives.The drop was driven by concerns over leadership uncertainty, financial strain and strategic direction. While&nbsp;<a href="https://stocktwits.com/symbol/LULU">Lululemon</a> and&nbsp;<a href="https://stocktwits.com/symbol/ALT">Altimmune</a> stock plummeted 13% and 16%, respectively,&nbsp; <a href="https://stocktwits.com/symbol/LCID">Lucid</a> tumbled over 9%.&nbsp;<h2 class="st-heading-2">LULU Faces Leadership Concerns</h2>Shares of Lululemon fell sharply after the company named a new CEO, set to take over in September. Investors reacted negatively to the delayed transition, particularly as North American sales showed signs of weakness.&nbsp;The leadership gap created uncertainty, prompting some shareholders to exit their positions rather than wait for a turnaround. The extended handover timeline has unsettled investors, who worry results could stay subdued until a new strategy takes shape. Many anticipate a quiet period before O’Neill steps in, with few major moves expected from interim co-CEOs Meghan Frank and André Maestrini.&nbsp;However, famed investor Michael Burry said he is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lulu-is-a-patience-trade-says-michael-burry-as-stock-dips-overnight-on-new-ceo-skepticism/cZBfmHQRebN">holding</a> his position in Lululemon and may buy more, noting it accounts for about 3.7% of his portfolio.&nbsp;<h2 class="st-heading-2">Lucid Struggles With Cash Burn</h2>Lucid’s stock hit record lows as investors focused on its financial health. Despite securing additional funding and appointing a new chief executive, concerns about ongoing losses and high production costs overshadowed optimism.&nbsp;Uber Technologies Inc. (UBER)&nbsp;earlier this week&nbsp;revealed it now owns roughly 37.75 million Lucid Class A shares, representing an 11.52% ownership position through a subsidiary. The filing confirms that Uber crossed the 10% threshold earlier this month, following a transaction completed on April 14, signaling deeper involvement between the two companies.<h2 class="st-heading-2">ALT Hit By Dilution Fears</h2>Altimmune also saw steep losses after announcing a large stock offering to fund clinical trials. The biotechnology firm, which is advancing its experimental treatment pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), announced details of its underwritten public offering on Thursday.&nbsp;Altimmune said the offering includes more than 64 million common shares, each paired with a warrant, priced at $3. The company expects to raise approximately $225 million in gross proceeds before expenses. Altimmune said it will direct the net funds toward its upcoming Phase 3 study in MASH.<h2 class="st-heading-2">What Are Retail Traders Saying?&nbsp;</h2>A Stocktwits user&nbsp;<a href="https://stocktwits.com/dumberdore/message/651231773">said</a> about Lucid, “Just the severe beating down is enough motivation for me to buy this stock at this price. I’m assuming just the parts and tech are worth more than the current market cap.”&nbsp;Commenting on Lululemon, another user said, “This company should just be sold if they can’t manage it better than this.”<stembedurl>https://stocktwits.com/StrayTrader/message/651234038</stembedurl>So far this year, LCID and LULU stocks have tanked by 40% and 31%, respectively, while ALT stock has sunk by 19%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/penn-stock-slips-overnight-after-year-s-high-ceo-says-employment-matters-more-than-gas-prices-for-casino-visits/cZBWFQdReTJ">PENN Stock Slips Overnight After Year's High: CEO Says Employment Matters More Than Gas Prices For Casino Visits</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lucid Group, Inc. is displayed on a smartphone screen, with a stock market chart in the background, on May 4, 2025. (Photo illustration by Cheng Xin/Getty Images)

LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? 

The decline was driven by concerns about factors ranging from leadership gaps and financial pressure to an unclear strategic direction. 

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.

<ul class="summary-bullets"><li>The offering is at a 13.5% discount to the stock’s closing price on Wednesday.</li><li>Altimmune plans to use the proceeds to support its Phase 3 trial of Pemvidutide in MASH, a liver disease.</li><li>The Phase 3 trial is expected to test multiple doses of Pemvidutide over 52 weeks.&nbsp;</li></ul>Shares of Altimmune Inc. (ALT) fell about 13% in pre-market trading on Thursday after the biotech company priced a $225 million public offering at a discount to its previous close, dampening investor sentiment.The company announced a public offering of roughly 64.3 million shares of common stock, along with warrants to purchase the same number of shares. Additionally, certain investors can opt for pre-funded warrants covering up to 10.75 million shares, each warrant paired with a common stock warrant. The combined offering price is set at $3 per share and accompanying warrant, or $2.999 for pre-funded warrant packages, Altimmune said.This represents a 13.5% discount to <a href="https://stocktwits.com/symbol/ALT">ALT stock’s</a> closing price of $3.47 on Wednesday.Altimmune plans to use the proceeds to support its Phase 3 trial of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease.Earlier in January, the firm announced a registered direct offering of about 17 million shares to raise around $75 million.<h2 class="st-heading-2">What’s The Status Of The Phase 3 Trial?</h2>In January, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Pemvidutide. The designation is intended to accelerate the development and review of treatments that show strong early evidence of meaningful improvement over existing options. The company also confirmed alignment with the FDA on Phase 3 trial plans following its end-of-Phase 2 meeting.The Phase 3 trial is expected to test multiple doses of Pemvidutide over 52 weeks, using liver biopsy-based endpoints to potentially support quick approval. The company has also submitted a request for scientific advice from European regulators.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits changed to ‘neutral’ from ‘bullish’ a day earlier. The update saw message volumes on the platform increase by 182% over a 24-hour period.One reader called it a “horror story.”<stembedurl>https://stocktwits.com/Roaring_Capybara/message/651111776</stembedurl>Another user expects more dilution.<stembedurl>https://stocktwits.com/Charlie50/message/651108878</stembedurl>The stock has declined around 10% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dell-stock-record-high-evercore-price-target-raise/cZBBxE7Reb3">DELL Stock’s Sharp Rally Takes It To All-Time High – Evercore Flags Surging AI Demand And Long-Term Deal Momentum</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Dilution Fears Return: Why ALT Stock Is Getting Hit Again 

The biotech company priced a $225 million public offering at $3 per share, its second offering this year.

ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’

Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M

Altimmune (NASDAQ:ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

ALTAltimmune Inc